Antibody

4개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved4 programs
AntibodyLimited DatastaleRochePhase 2

131I-rituximab (131I-rituximab)

Relapsed or Refractory Follicular Lymphoma or Mantle Cell Lymphoma · FRα

#FR#Antibody#Phase2#monoclonal-antibody#RelapsedorRefractoryFollicularLy+1
Trials 4Status Active
AntibodyLimited DatastaleADC TherapeuticsPhase 1

durvalumab (Imfinzi, Loncastuximab Tesirine and Durvalumab)

Diffuse Large B-Cell Lymphoma; Mantle Cell Lymphoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#Antibody#Phase1#monoclonal-antibody#MantleCellLymphoma+1
Trials 1Status Discontinued
AntibodyLimited DatastaleInnoventPhase 2

PD-1 inhibitor (Sintilimab, Sintilimab (PD-1 inhibitor))

Large B Cell Diffuse Lymphoma; Mantle Cell Lymphoma (MCL) · PD-1

#PD-1#Antibody#Phase2#monoclonal-antibody#LargeBCellDiffuseLymphoma+2
Trials 1Status Recruiting
AntibodyLimited DatastaleCABYCPhase 2

Y-90 Ibritumomab tiuxetan (Y-90 Ibritumomab tiuxetan)

Mantle Cell Lymphoma · Mantle Cell Lymphoma

#MantleCellLymphoma#Antibody#Phase2#monoclonal-antibody#CABYC
Trials 1Status Active